Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 0.98% 51.50 50.00 53.00 54.00 51.50 51.50 471,428 16:16:05
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -1.9 -2.3 - 44

OptiBiotix Health PLC Manufacturing, supply and profit sharing agreement

12/08/2019 7:00am

UK Regulatory (RNS & others)

Optibiotix Health (LSE:OPTI)
Historical Stock Chart

6 Months : From May 2019 to Nov 2019

Click Here for more Optibiotix Health Charts.


RNS Number : 6240I

OptiBiotix Health PLC

12 August 2019

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Manufacturing, supply and profit sharing agreement with Maxum Foods Pty Ltd.

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skin care, announces it has entered into a manufacturing, supply and distribution agreement with Maxum Foods Pty Ltd ("Maxum"). The agreement grants Maxum an exclusive license to manufacture, supply and distribute OptiBiotix's SlimBiome(R) weight management technology in Australia and New Zealand.

Founded in 2003, Maxum is an Australia-based dairy supplier headquartered in Brisbane and operating a dry blending facility in Melbourne, as well as distribution centres throughout Australia and New Zealand. Maxum has been named one of Australia's fastest-growing SMEs on the 2018 Smart50 list with a turnover of AUS$150.7 million in 2018 and a 110% growth between 2016 and 2018.

SlimBiome(R), an award winning weight management product, will be supplied by Maxum as a specialised functional ingredient, into a wide range of applications including, but not limited to, human nutrition comprising food and beverages, dairy, dietary supplements and sports nutrition.

This is another strategic step by OptiBiotix to derisk its supply chain and extend the market reach of SlimBiome(R) by adding manufacturing in Australia. Partnering with an established distributor that services over 950 customers and to whom it sells approximately 35,000 metric tonnes of dairy per year, will extend the commercial opportunity for OptiBiotix's patented award winning weight management product into the Australian weight management market which is estimated to be worth AUS$320 million in 2019 (source:

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are pleased to announce the signing of a manufacturing and supply agreement with Maxum. We chose Maxum due to their knowledge of the Australian and New Zealand markets as well as their experience in distributing specialty ingredients like SlimBiome(R) and their reputation for supplying high-quality products to the food industry. We believe working with Maxum, and similar partners around the world, provides the best opportunity of increasing our global commercial reach and catering to the growing interest we are seeing in SlimBiome(R) from partners worldwide."

Dustin Boughton, Director of Maxum stated: "We are excited to be working with OptiBiotix in Australia and New Zealand. Our logistical and technical expertise and access to distribution channels within these markets means this is a natural fit for both companies. The manufacturing and supply of SlimBiome(R) is aligned with our goal of bringing innovative and high quality products to our customers."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 OptiBiotix Health plc                         
 Stephen O'Hara, Chief Executive                      Contact via Walbrook 
 Cairn Financial Advisers LLP (NOMAD)                   Tel: 020 7213 0880 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 finnCap (Broker)                                       Tel: 020 7220 0500 
 Geoff Nash / Kate Bannatyne (Corporate Finance) 
 Camille Gochez (Corporate Broking) 
 goetzpartners securities Limited                       Tel: 0203 859 7725 
 Ulrich Kinzel 
 Walbrook PR Ltd                                        Mob: 07876 741 001 
 Anna Dunphy 

About OptiBiotix -

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

August 12, 2019 02:00 ET (06:00 GMT)

1 Year Optibiotix Health Chart

1 Year Optibiotix Health Chart

1 Month Optibiotix Health Chart

1 Month Optibiotix Health Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191120 05:18:52